U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07255898) titled 'A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies' on Nov. 20.
Brief Summary: This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-M24D1 in patients with relapsed or refractory multiple myeloma and other hematologic malignancies.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Hematologic Malignancies
Intervention:
DRUG: BL-M24D1
Administration by intravenous infusion for a cycle of 2 weeks.
Recruitment Statu...